A Double-Blind Placebo-Controlled Clinical Evaluation of Multistem for the Treatment of Ischemic Stroke
Authors:
- 22 May 2013
- journal article
- research article
- Published by SAGE Publications in International Journal of Stroke
- Vol. 9 (3) , 381-386
Abstract
Background: There is growing interest in neurorestorative and reparative therapies after acute stroke. MultiStem® is an allogeneic cell therapy treatment comprising a population of multipotent adherent bone marrow cells that has shown safety in clinical trials of myocardial infarction and graft vs. host disease, as well as preclinical evidence of activity in stroke and other neurological damage models. MultiStem is now being evaluated in a clinical trial in patients that have suffered an ischemic stroke, in which the product is administered intravenously 24–36 h after the ischemic event. Methods: The Phase 2 randomized, double-blind, placebo-controlled, multicenter dose-escalation trial will consist of three treatment cohorts, including a placebo group, and two treatment groups involving dose tiers of either 400 million or 1200 million cells per patient. Patients will be treated at 24–36 h after stroke. The two primary objectives are to determine the highest well-tolerated and safe single dose of MultiStem up to a maximum of 1200 million total cells in subjects with ischemic stroke and to determine the efficacy of MultiStem on functional outcome in subjects with stroke as measured by the modified Rankin Scale at 90 days. Patients will also be evaluated using the National Institutes of Health Stroke Scale and Barthel Index. The study will explore other aspects including, uniquely, the measurement of spleen size after stroke by magnetic resonance imaging or computed tomography imaging. Conclusions and future direction: If MultiStem is safe and there is a signal of efficacy, a late stage phase IIb-III trial is planned.Keywords
This publication has 32 references indexed in Scilit:
- Efficiency Perspectives on Adaptive Designs in Stroke Clinical TrialsStroke, 2011
- Donor Myocardial Infarction Impairs the Therapeutic Potential of Bone Marrow Cells by an Interleukin-1–Mediated Inflammatory ResponseScience Translational Medicine, 2011
- Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective TherapiesStroke, 2011
- Multipotent Adult Progenitor Cells Prevent Macrophage-Mediated Axonal Dieback and Promote Regrowth after Spinal Cord InjuryJournal of Neuroscience, 2011
- Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen ActivatorStroke, 2009
- S tem Cell T herapies as an E merging P aradigm in S troke (STEPS)Stroke, 2009
- Hematopoietic Stem Cells Reduce Postischemic Inflammation and Ameliorate Ischemic Brain InjuryStroke, 2008
- Transplantation of Cryopreserved Human Bone Marrowderived Multipotent Adult Progenitor Cells for Neonatal Hypoxie- Ischemic Injury: Targeting the HippocampusReviews in the Neurosciences, 2006
- RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrowNature, 2002
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995